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1. Introduction 
The melanocortin system includes the melanocortins, their receptors and two endogenous 
antagonists. This system is involved in several physiological processes in the brain. 
Melanocortins have potent anti-inflammatory and neuroprotective effects in the central 
nervous system (CNS). Therefore, they are suitable candidates for the treatment of 
inflammatory and neurodegenerative disorders within the brain.  
2. Melanocortins 
Melanocortins include , , and -melanocyte stimulating homones (MSH), and 
adrenocorticotropin (ACTH). These neuropeptides derive from pro-opiomelanocortin 
(POMC) proteolytic cleavage (Fig. 1). POMC is a 31 KDa pro-hormone that is processed by 
pro-hormone convertases (PCs) in secretory vesicles of the cell. PCs belong to the family of 
serine proteases and recognize pairs of basic amino acid residues. PC expression is tissue 
specific and their presence induces secretion of different products generated from POMC, 
thereby determining melanocortins’ selective expression (Bicknell, 2008). Intact POMC was 
also shown to be released into the circulation (Gibson et al., 1994). -MSH is produced in the 
presence of PC1 and PC2 (Benjannet et al., 1991) and additional modifications such as 
glycosylation, phosphorylation, amidation, and acetylation may occur. For example, 
acetylation gives -MSH increased resistance to degradation, this modification resulting in 
increased biological activity (Wilkinson, 2006).  
Although -MSH is synthesized in several tissues such as skin, placenta, testis, ovary, 
kidney, and adrenal gland, the main source of -MSH is the pars intermedia of the pituitary 
gland (Usategui et al., 1976). In the CNS, -MSH is produced in the arcuate nucleus of the 
hypothalamus (O´Donohue & Dorsa, 1982) and in the nucleus of the solitary tract in the 
brain stem (Bronstein et al., 1992). Melanocortin fibers project from these sites to the 
paraventricular nucleus, the lateral hypothalamus, and throughout the brain, e.g., 
amygdala, hippocampus, nucleus accumbes, and spinal cord (Bagnol et al., 1999). ACTH is 
produced mainly in the anterior pituitary gland and released into circulation, although it is 
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also expressed in the skin (Wakamatsu et al., 1997). -MSH was detected in adrenal medulla 
(Bjartell et al., 1987), intestine neurons (Wolter, 1985), and the brain (Kawai et al., 1984) 
whereas -MSH was found in human hypothalamus (Bertagna et al., 1986), but not in rodent 
brain. All melanocortins share a conserved sequence of aminoacids: Met-Glu(Gly)-His-Phe-
Arg-Trp necessary for their biological activity. Rare mutations in POMC gene have been 
found in humans, and are associated with severe early-onset obesity, adrenal insufficiency 
and red hair pigmentation (Krude et al., 1998). 
 
Fig. 1. Hypothalamic post-translational processing of POMC. PC1 (also known as PC3) 
cleaves POMC protein to generate pro-ACTH and -lipotropin (-LPH). Pro-ACTH is 
further cleaved by PC1 to generate ACTH and N-terminal peptide (N-POC). In the brain 
and in the intermediate lobe of pituitary, PC2 cleaves ACTH to generate corticotropin-like 
intermediate peptide (CLIP) and -MSH. Then, two more peptidases, carboxipeptidase E 
and peptidyl -amidating monooxygenase, are needed to produce mature -MSH. PC2 also 
generates -lipotropin (-LPH) and -endorphin (-END) from -LPH cleavage, -MSH from 
-LPH, and -MSH from N-POC cleavage.  
2.1 Melanocortin receptors 
Cloning of melanocortin receptors (MCRs) led to the characterization of five distinct MCRs 
which help to explain the wide range of physiological functions of melanocortins. Each 
receptor is the product of a small, intronless separate gene. MCRs belong to class A of seven 
transmembrane G protein-coupled receptors (GPCRs) and are positively coupled to 
adenylate cyclase. MCRs exhibit sequence homology from 40% to 60%. All MCRs have 
several potential N-glycosylation sites in their N-terminal domains, conserved cysteine 
residues in their carboxyl termini for potential acetylation with fatty acids, and consensus 
recognition sites for protein kinase A (PKA) and C. ACTH, -MSH, and -MSH are agonists 
of all MCRs except MC2R which only recognizes ACTH (Schiöth et al., 1996), whereas -
MSH is a selective MC3R agonist (Roselli-Rehfuss et al., 1993) (Table 1). 
MC1R was the first receptor cloned from a melanoma cell line (Chhajlani & Wikberg, 1992) 
and from normal melanocytes (Mountjoy et al., 1992), and is expressed predominantly in the 
skin where it mediates -MSH induction of melanogenesis. MC1R mutations are associated 
with increased risk of developing melanoma (Kennedy et al., 2001). MC1R is also found in 
immune cells such as macrophages (Lam et al., 2005), monocytes (Bhardwaj et al., 1997), 
neutrophils (Catania et al., 1996), and B lymphocytes (Cooper et al., 2005). It is also 
expressed in endothelial cells (Hartmeyer et al., 1997) and fibroblasts (Böhm et al., 1999). 
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MC1R is involved in the anti-inflammatory action of -MSH in leukocytes (Taherzadeh et 
al., 1999). Indeed, MC1R involvement in the anti-inflammatory effects of melanocortins has 
been widely studied in peripheral cells (Catania et al., 2004). Recently, MC1R expression 
was also found in rat heart (Catania et al., 2010). In the CNS, MC1R was detected only in 
neurons of periaqueductal grey matter (Xia et al., 1995) and in mouse brain (Rajora et al., 
1997a). However, nothing is known about the role of MC1R in central effects of 
melanocortins.  
MC2R is present in the adrenal gland and is selectively activated by ACTH leading to 
production and release of steroids (Mountjoy et al., 1992). Mutations in MC2R gene that 
produce a non functional receptor are associated with familial glucocorticoid deficiency 
(Elias et al., 1999), a rare autosomal recessive disorder. MC2R is also present in rodent 
adipocytes (Boston & Cone, 1996), suggesting a role for melanocortins in lipolysis, although 
it was not found in human adipocytes (Chhajlani, 1996). MC2R was found in human 
keratinocytes where its activation by ACTH induced cortisol synthesis (Slominski et al., 
1996), and it was recently shown to be present in bone cells as well (Isales et al., 2010). 
MC3R is widely distributed in the CNS, highly expressed in the hypothalamus and the 
limbic system (Roselli-Rehfuss et al., 1993). It has been proposed to function as an auto-
receptor since it is expressed in POMC neurons where it might regulate melanocortin 
release (Jégou et al., 2000). However, MC3R knock-out mice are obese and hyperphagic and 
have increased fat mass (Chen et al., 2000), indicating that MC3R may have other actions in 
the brain. MC3R is present in the digestive tract in stomach, duodenum and pancreas and in 
human placenta (Gantz et al., 1993), as well as in human heart, kidney, testis, ovary, 
mammary gland, and skeletal muscle (Chhajlani, 1996). Immune cells such as macrophages 
(Lam et al., 2005) and B lymphocytes (Cooper et al., 2005) express this receptor which is 
involved in anti-inflammatory effects of melanocortins in macrophages (Getting et al., 2006). 
MC3R plays a role in sodium homeostasis having natriuretic actions (Lin et al., 1987) and 
has protective effects in heart ischemia in rats (Guarini et al., 2002).  
MC4R is expressed throughout the brain including the cortex, thalamus, hypothalamus, and 
the spinal cord (Gantz et al., 1994; Mountjoy et al., 1994), and it was shown to be more 
widely distributed than MC3R in the brain. Outside the CNS, it has been detected in human 
adipose tissue (Chhajlani, 1996), and it was recently detected in human epidermal 
melanocytes where it regulates pigmentation (Spencer & Schallreuter, 2009). MC4R is 
involved in neuroendocrine and autonomic functions, being a key factor in the regulation of 
food intake and metabolism (Huszar et al., 1997). The anorexigenic effect of -MSH involves 
this receptor (Marsh et al., 1999). In this regard, mutations in MC4R gene in humans are 
associated with obesity (Yeo et al., 1998) and are now considered the most common 
monogenic cause of obesity. In contrast, no MC3R variants are associated with obesity in 
humans. MC4R is also involved in the antipyretic actions of -MSH (Sinha et al., 2004), and 
it also mediates the neurotrophic effect of -MSH on cultured neurons (Adan et al., 1996) 
and on neurite elongation of dorsal root ganglia neurons (Tanabe et al., 2007). MC4R is 
involved in melanocortins anti-inflammatory action in the brain (Lasaga et al., 2008). MC4R 
is the only MCR expressed in astrocytes (Selkirk et al., 2007; Caruso et al., 2007) where it 
exerts anti-inflammatory effects (Caruso et al., 2007). We recently showed that hypothalamic 
cultured neurons express MC4R and MC3R, and -MSH also exerts an anti-inflammatory 
action on these cells (Caruso et al., 2010). Activation of MC4R in astrocytes also induces the 
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expression of brain-derived neurotrophic factor (BDNF) (Caruso et al., 2011), which suggests 
that BDNF could mediate melanocortins effects.  
MC5R is found in adipocytes, kidney, liver, lung, bone marrow, thymus, mammary gland, 
testis, ovary, uterus, pituitary, stomach and skin (Chhajlani, 1996; Gantz et al., 1994; Labbé et 
al., 1994; van der Kraan et al., 1998). Observation of MC5R knock-out mice indicates that its 
main functions involve regulation of lacrimal glands and of secretion of sebaceous glands 
(Chen et al., 1997). These mice showed no changes in anti-inflammatory, neuroprotective or 
analgesic actions induced by administration of -MSH. MC5R was also found in the adrenal 
gland (Liakos et al., 1998) where -MSH induces aldosterone production in vitro, although 
to a lesser extent. MC5R is expressed in B and T lymphocytes, indicating that it could be 
involved in immune regulation. This receptor has also been detected in some areas of the 
CNS but its physiological functions are unknown (Griffon et al., 1994). 
 
Table 1. Ligand, function and distribution of MCRs 
The melanocortin system is unique in that it is the only system with endogenous 
antagonists. The Agouti protein (Miller et al., 1993) produced in the skin of rodents is a 
competitive antagonist of MC1R and also of MC4R albeit with lower affinity (Blanchard et 
al., 1995). In humans, Agouti is expressed in the skin, adipose tissue, testis, ovary, liver, 
heart and kidney (Wikberg et al., 2000) and regulates skin pigmentation. The Agouti-related 
protein (AGRP) was cloned based on its homology with Agouti (Shutter et al., 1997). It is 
present in the brain only in neurons of the arcuate nucleus (Dinulescu & Cone, 2000) where 
it promotes increased feeding and decreased energy expenditure by binding MC4R (Cone, 
2005). Ubiquitous expression of AGRP causes obesity in mice (Ollman et al., 1997). AGRP is 
a competitive antagonist of MC3R and MC4R and it was shown to inhibit constitutive MC4R 
activity (Haskell-Luevano & Monek, 2001). 
2.2 MCR signaling pathways 
The classical signaling pathway for MCRs couples to stimulatory G protein that activates 
adenylate cyclase and increases intracellular cyclic AMP (cAMP) production. In turn, cAMP 
www.intechopen.com
 
Melanocortins: Anti-Inflammatory and Neuroprotective Peptides 
 
97 
can activate PKA. This kinase was reported to be involved in melanocortins effects in 
melanoma cells (Ao et al., 1998) and in adrenal cells (Roy et al., 2011). In Agouti mice PKA 
constitutive activity even rescued mice from obesity syndrome (Czyzyk et al., 2008). As a 
result of its activation, PKA can phosphorylate and activate the cAMP responsive element 
binding protein (CREB), which then acts within the nucleus as a transcription factor. CREB 
is activated by -MSH in neurons of the hypothalamic paraventricular nucleus (Sarkar et al., 
2002), in neurons of the solitary nucleus (Sutton et al., 2005), in hypothalamic cultured 
neurons (Caruso et al., 2010), and also in cultured rat astrocytes (Caruso et al., 2011). Apart 
from the cAMP-PKA-CREB pathway MCRs also activate other signaling pathways. MC3R 
has been shown to induce inositol phosphate signaling (Konda et al., 1994) and MC5R was 
reported to activate the Janus kinase/signal transducer and activator of transcription 
(Jak/STAT) pathway in B cells (Buggy, 1998). Stimulation of all MCRs leads to activation of 
mitogen-activated protein kinases (MAPK) ERK-1/2 (Chai et al., 2006; Chai et al., 2007; 
Herraiz et al., 2011; Patten et al., 2007, Rodrigues et al., 2009; Roy et al., 2011). Depending on 
the cell type this effect may involve phosphoinositol 3 kinase activation (Rodrigues et al., 
2009; Vongs et al., 2004). Some reports also show that ERK activation may be PKA-
independent in MCR transfected cell lines (Chai et al., 2006; Vongs et al., 2004). Intracellular 
calcium is also elevated by MC1R, MC3R, and MC4R stimulation (Eves et al., 2003; Konda et 
al., 1994; Newman et al., 2006). Although these data show some insight into MCR signaling, 
much work is still needed to fully elucidate signaling pathways of MCRs and to evaluate 
their importance in in vivo models. Pathways may also interact with each other as cross-talk 
between receptors, adding complexity to the picture. For example, MC4R activation 
enhances insulin-stimulated mTOR signaling (Chai et al., 2010) and potentiates leptin 
signaling (Zhang et al., 2009).  
In addition to G proteins, MCRs can interact with other proteins that regulate their function. 
Some accessory proteins help folding and trafficking GPCRs to the cell membrane whereas 
others are found associated with the receptor and are involved in ligand binding. It is now 
established that a functional MC2R requires the expression of melanocortin 2 receptor 
accessory protein (MRAP). MRAP interacts with MC2R and facilitates MC2R cell surface 
expression, thereby producing an ACTH-responsive receptor (Webb et al., 2009). MRAP 
has two isoforms, MRAP and MRAP, both expressed in the human adrenal gland 
(Metherell et al., 2005). Both MRAP isoforms interact directly with MC2R enabling ligand 
binding and activation (Roy et al., 2007). Individuals lacking MRAP have familial 
glucocorticoid deficiency disease (Metherell et al., 2005), which highlights the role of 
MRAP in MC2R functionality. Another accessory protein, MRAP-2, is expressed in the 
brain and the adrenal gland (Chan et al., 2009). MRAP and MRAP-2 act as negative 
regulators of MCRs other than MC2R since they reduce cAMP production in response to 
receptor activation (Chan et al., 2009). In addition, mahoghany, mahoganoid (also called 
mahogunin ring finger-1), and syndecan-3 were identified as accessory proteins for 
MCRs. Mahoghany, a transmembrane protein present in the brain and skin, was shown to 
be a low-affinity receptor for Agouti but not for AGRP (He et al., 2001). Recently, 
mahoganoid was shown to reduce MC1R and MC4R coupling to cAMP (Perez-Oliva et al., 
2009). Finally, syndecan-3 is a proteoglycan that enhances AGRP antagonism of -MSH at 
MC4R (Reizes et al., 2003). In spite of all this evidence, interaction between MCRs and 
accessory proteins is still not fully understood. 
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2.3 Synthetic compounds acting on MCRs 
Some synthetic compounds for MCRs have been developed. (Nle4, D-Phe7) -MSH (NDP-
MSH), also known as melanotan I (MTI), is the most potent linear analogue of -MSH 
(Sawyer et al., 1980). It shows high affinity for all MCRs and has been widely used in 
radioligand binding studies. Other agonist peptides are melanotan II (MTII), a small cyclic 
peptide that is a non selective agonist of all MCRs except MC2R, and HP-228, a linear 
analogue that is also a non selective agonist for MCRs but shows greater affinity for MC1R 
(Abou-Mohamed et al., 1995). Several MC4R agonists have also been developed. Ro27-3225 
is a full agonist in human cells that express MC4R (Benoit et al., 2000) and was shown to 
protect against haemorrhagic shock (Giuliani et al., 2007b). Also, THIQ is a MC4R agonist 
that reduced food intake less effectively than MTII (Muceniece et al., 2007). Antagonists 
have also been developed. SHU9119 is a potent non-selective antagonist of MC3R and 
MC4R (Schiöth et al., 1999). HS014 (Schiöth et al., 1999), is the first selective MC4R 
antagonist since it has 20-fold higher affinity for MC4R over MC3R. HS024 is a competitive 
analog of -MSH (Kask et al., 1998) with 100 times more affinity for MC4R over MC3R, 
although it antagonizes cAMP accumulation induced by all MCRs except MC2R. All 
antagonists stimulate food intake when administered centrally. 
3. Anti-inflammatory effects of melanocortins 
Inflammation is a physiological response to infection or tissue damage which, if properly 
controlled, ultimately leads to the restoration of homeostasis. Cytokines, chemokines, nitric 
oxide (NO) and prostaglandins (PGs) are mediators of inflammatory processes that induce 
vasodilation and extravasation of immune cells into injured tissues, activation of pathogen 
clearance mechanisms and tissue regeneration. These factors have also been linked to the 
pathology of several CNS disorders with an exacerbated inflammatory component, such as 
Alzheimer´s disease (AD), Parkinson disease (PD), multiple sclerosis (MS), HIV infection, 
and brain ischemia/reperfusion. Among their many physiological functions, melanocortins 
play an important role in the regulation of immune and inflammatory reactions. These 
effects can be exerted through their binding to centrally expressed MCRs which in turn 
regulate descending neural anti-inflammatory pathways, or by acting directly on immune 
cells or non-immune cells present in peripheral tissues (Lasaga et al., 2008), where they 
modulate the production of inflammatory mediators and the migration of inflammatory 
cells. Different MCRs may be responsible for the anti-inflammatory properties of 
melanocortins depending on the tissue or cell type involved. MC1R, MC3R and MC5R are 
the subtypes most commonly associated with these peripheral effects, whereas MC3R and 
MC4R are more likely responsible for melanocortins anti-inflammatory action within the 
CNS. Some studies also indicate that alternative non-MCR-mediated pathways may be 
involved in the signaling of certain melanocortin peptides such as -MSH (Langouche et al., 
2002) and -MSH C-terminal tripeptide Lys-Pro-Val (KPV). 
3.1 Peripheral effects 
3.1.1 In vitro studies 
Melanocortins effects on peripheral tissues have been studied in a broad range of in vitro 
systems, particularly in immune cells where they appear to act mainly by decreasing the 
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production and release of inflammatory mediators and impairing leukocyte activation and 
infiltration into damaged tissues. For instance, it was shown that -MSH inhibits synthesis 
and release of pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis 
factor- (TNF-), interferon- (IFN-), and IL-2 in cells of the immune system (Lipton et al., 
1999; Luger et al., 2003; Manna et al., 2006; Star et al., 1995; Taherzadeh et al., 1999). It 
enhances the release of the anti-inflammatory cytokine IL-10 in monocytes (Bhardwaj et al., 
1996) and keratinocytes (Redondo et al., 1998) as well. -MSH can also inhibit chemokine 
production in a human retinal epithelial cell line that expresses MC1R (Cui et al., 2005), and 
IL-8 in fibroblasts and in human adipocytes, (Böhm et al., 1999, 2002). Melanocortins 
modulate the expression of adhesion molecules in response to inflammatory stimuli. For 
instance, -MSH inhibits the expression of adhesion molecules induced by LPS or TNF- in 
endothelial cells (Scholzen et al., 2003), leading to impaired lymphocyte adhesion. Another 
target of melanocortins is the inducible NO synthase (iNOS). This enzyme is induced by 
inflammatory stimuli and produces a high output of NO, a short-lived molecule which 
plays a major role in the regulation of immune, nervous and cardiovascular systems. 
Beyond its many physiological roles, excessive NO production may be harmful and mediate 
tissue damage and cell death. Several studies indicate that melanocortin peptides exert a 
protective role by inhibiting iNOS expression in stimulated macrophages, thus leading to 
decreased NO production (Mandrika et al., 2001; Star et al., 1995; Taylor, 2005). PGs are a 
family of lipid molecules derived enzymatically from fatty acids with a broad spectrum of 
physiological functions. They participate in multiple homeostatic effects and play a dual role 
in immunomodulation, different members of the family being involved in both the onset 
and resolution of the inflammatory response. Their production is catalyzed by 
cyclooxygenase (COX) 1 and 2, COX-2 being the isoform specifically activated by 
inflammation. -MSH inhibits pro-inflammatory PG synthesis from fibroblasts induced by 
IL-1 (Cannon et al., 1986). Furthermore, in melanocyte and keratinocyte cell lines -MSH 
was shown to reduce the release of PGE2 induced by TNF- (Nicolaou et al., 2004).  
3.1.2 In vivo studies 
Some of the in vivo anti-inflammatory actions of melanocortins in the periphery are due to 
ACTH binding to its receptor MC2R in the adrenal cortex which promotes the production of 
glucocorticoids with a consequent systemic anti-inflammatory response. Melanocortin 
peptides can have anti-inflammatory effects acting via central MCRs through descending 
neurogenic pathways or directly on peripheral tissues through other MCR subtypes. Both -
MSH and -MSH are capable of inhibiting the effects of IL-1 on the activation of the 
hypothalamic-pituitary-adrenal axis by acting on central melanocortin receptors (Cragnolini 
et al., 2004). Several studies show that systemic and/or central administration of -MSH 
exerts protective effects in diverse models of peripheral inflammation. Circulating levels of 
-MSH have also been shown to be increased in inflammatory diseases such as rheumatoid 
arthritis, MS, PD, and HIV infection (Catania et al., 2000). Anti-inflammatory actions of 
melanocortins have been widely studied in animal models of systemic inflammation such as 
septic shock where -MSH has been shown to reduce circulating levels of pro-inflammatory 
cytokines TNF- and IL-1 (Gonindard et al., 1996) and to improve animals’ survival rate 
from 10% to 50% by 24 h (Lipton et al., 1994). Treatment with ACTH and POMC-derived 
peptides was also shown to inhibit cytokine release and neutrophil migration in a mouse 
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model of acute experimental inflammation (Getting et al., 1999). In a model of acute 
hepatitis induced by LPS, Chiao et al. (1996) showed that -MSH was able to prevent liver 
inflammation by inhibiting NO production, TNF- and IL-8 mRNA increase, and neutrophil 
infiltration. -MSH was also shown to reduce chemokine synthesis and prevent damage to 
lungs and kidneys under hypoxic conditions in a model of renal ischemia (Chiao et al., 1997; 
Deng et al., 2004). It also reduced heart injury and size of the ischemic area in a rat model of 
myocardial ischemia, through activation of MC3R (Bazzani et al., 2001; Guarini et al., 2002). 
Research on experimental inflammatory bowel disease showed that treatment with -MSH 
effectively reduces inflammatory mediators in experimental colitis (Rajora et al., 1997b). As 
for skin inflammation, both centrally and locally administered -MSH has been shown to 
modulate the cutaneous immune response in several mouse models of contact dermatitis or 
cutaneous vasculitis (Brzoska et al., 2008). Furthermore, this peptide was proved to induce 
hapten-specific tolerance in vivo by a mechanism involving IL-10 as a crucial mediator 
(Grabbe et al., 1996). Since -MSH and MC1R protein levels are up-regulated in human 
burns and scars a role in cutaneos injury is also suggested (Muffley et al., 2011). A gene 
therapy approach based on an -MSH expression vector has been tested in a model of 
experimental autoimmune uveitis, in which the treatment was successful in suppressing this 
condition by a mechanism dependent on MC5R expression, suggesting that this approach 
might provide effective therapy for uveitis (Lee et al., 2009).  
MC1R involvement in the anti-inflammatory effects of melanocortins has been widely 
observed in peripheral cells (Catania et al., 2004). Recently, it was shown that the selective 
MC1R agonist BMS-470539 was succesful in inhibiting leukocyte trafficking in the 
vasculature of mice subjected to mesenteric ischemia-reperfusion. This anti-inflammatory 
effect was lost when examining the vasculature of mice with mutant inactive MC1Rs (Leoni 
et al., 2010), indicating that MC1R plays a prominent role in melanocortins effects. In models 
of allergic and nonallergic lung inflammation, melanocortins inhibited leukocyte 
accumulation, a protective effect that was associated with MC3R activation (Getting et al., 
2008). On the other hand, Ro27-3225, a selective MC4R agonist, reduced the expression of 
TNF- and IL-6, and reduced pancreatitis severity, effects that were blocked by HS024, a 
selective MC4R antagonist (Minutoli et al., 2011). On the other hand, several MCR-
independent effects of melanocortin C terminal sequence-derived peptides were described. 
The melanocortin-derived tripeptide KPV was shown to reduce the inflammatory infiltrate 
in a model of inflammatory bowel disease, leading to recovery (Kannengiesser et al., 2008). 
Another synthetic peptide (CPVK)2 also showed anti-inflammatory activity similar to NDP-
MSH against endotoxin treatment in vitro and in vivo by reducing TNF- and NO 
production (Gatti et al., 2006). The mechanism of action of these peptides seems to involve 
interaction with the IL-1 receptor I, thereby preventing IL-1 binding (Mastrofrancesco et 
al., 2010). 
3.2 Central effects 
3.2.1 In vitro studies 
Inflammatory reactions within the CNS constitute a physiological host-defense mechanism 
by which damaging agents are cleared and tissue homeostasis is restored. As part of this 
response, glial cells become reactive and release a wide variety of inflammatory mediators 
such as cytokines, chemokines, complement factors and acute phase reactants. These factors 
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are necessary for an adequate immune or inflammatory response, but if the response is not 
properly controlled, they may also lead to tissue damage and cytotoxicity. Therefore, the 
discovery of compounds with the ability to modulate inflammatory responses in the brain is 
of paramount importance.  
Activation of MCRs in the brain is known to be essential to the anti-inflammatory circuit of 
melanocortins. Expression of MC1R (Xia et al., 1995; Rajora et al., 1997a) and MC5R (Griffon 
et al., 1994) has been described but their physiological functions in the CNS are unknown. 
Considering that -MSH has anti-inflammatory action in brain of mice with non-functional 
MC1R (Ichiyama et al., 1999), this receptor may not be an important mediator of anti-
inflammatory effects of melanocortins in the CNS. Therefore, the main candidates to 
mediate central effects of melanocortins are MC3R and MC4R since these are the subtypes 
expressed in the brain. Astrocytes are the most abundant glial cell population in the brain. 
The only MCR subtype found in these cells is MC4R (Caruso et al., 2007; Selkirk et al., 2007). 
On the other hand, subtypes 1, 3, 4 and 5 were detected in a human microglial cell line 
(Lindberg et al., 2005). Melanocortins were shown to inhibit production of IL-6, TNF- and 
NO in a murine microglial cell line, where endogenous -MSH released from microglial 
cells was proposed to act as an autocrine immunomodulatory factor (Delgado et al., 1998). 
They also inhibited the release of both NO and TNF- from microglia stimulated with -
amyloid peptides and IFN- (Galimberti et al., 1999), suggesting that these peptides might 
modulate the local response to -amyloid deposition. In human astrocytoma cells, -MSH 
inhibits LPS-induced TNF- release (Wong et al., 1997). We showed that -MSH attenuates 
LPS+IFN--induced inflammation in rat astrocytes by decreasing iNOS and COX-2 
expression and NO and PGE2 release (Caruso et al., 2007). These effects were prevented by 
HS024, strongly suggesting a role for MC4R in brain anti-inflammatory melanocortin effects. 
However, -MSH had no effect on basal or IL-1-induced PGE2 levels in astrocytes 
(Katsuura et al., 1989), although it inhibited LPS- or IL-1-induced PGE2 production from 
hippocampus fragments (Weidenfeld et al., 1995), but not IL-1-induced PGE2 release from 
hypothalamic fragments (Mirtella et al., 1995). We recently showed that hypothalamic 
neurons express MC3R and MC4R and that -MSH reduces TNF- expression in these cells 
where it induces CREB activation (Caruso et al., 2010).  
3.2.2 In vivo studies 
A typical reaction to inflammatory processes in the CNS is the induction of fever as a host-
defense response. Melanocortin anti-pyretic action has been known for some time (Tatro, 
2000) and is considered adrenal-independent (Murphy et al., 1983). -MSH central 
administration reduces fever caused by LPS (Huang et al., 1997), IL-1 (Daynes et al., 1987) 
and TNF- (Martin et al., 1991). Also, during fever episodes, levels of -MSH increase in the 
brain (Bell & Lipton, 1987) suggesting a physiological role for melanocortins in fever control. 
-MSH circulating levels increase in response to endotoxin administration in humans 
(Catania et al., 1995). Intraperitoneal (i.p.) administration of -MSH was shown to inhibit 
fever by activating central MCRs, since their blockade prevented an -MSH anti-pyretic 
effect (Huang et al., 1998). This effect was also blocked by HS014, a selective MC4R 
antagonist, thereby highlighting MC4R involvement in -MSH effect over LPS-induced 
fever (Sinha et al., 2004). Central administration of -MSH in mice reduces the expression of 
iNOS in lungs and liver and serum TNF- levels induced by endotoxemia (Delgado 
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Hernandez et al., 1999). Conversely, i.p. injection of -MSH has no effect over endotoxemia-
induced iNOS expression in lung and liver, supporting the notion that activation of central 
MCRs is responsible for the peripheral anti-inflammatory effect of -MSH. Moreover, 
treatment with -MSH reduces expression of TNF- and IL-1 after cerebral ischemia 
(Huang & Tatro, 2002), lowers TNF- and NO production induced by LPS+IFN- in the 
CNS (Delgado et al., 1998), and also reduces TNF- production in brain inflammation 
(Rajora et al., 1997a). Furthermore, melanocortins inhibit the IL-1-induced production of 
NO and PGs in rat hypothalamus (Cragnolini et al., 2006). We demonstrated that -MSH 
reduces induction of iNOS and COX-2 gene expression at hypothalamic level in rats during 
endotoxemia, and that this effect is mediated by MC4R activation (Caruso et al., 2004). 
Together with -MSH, -MSH and -MSH were found to exert anti-inflammatory action in a 
model of neuroinflammation in mice by reducing LPS-induced NO production (Muceniece 
et al., 2004).  
3.3 Mechanisms of anti-inflammatory actions of melanocortins 
The nuclear factor-B (NF-B) is an essential regulator of the immune response since it 
drives the expression of several pro-inflammatory genes such as cytokines, chemokines, 
iNOS and COX-2 induced by diverse inflammatory stimuli (Li & Verma 2002). Under 
resting conditions it is held within the cytoplasm in an inactive state by its inhibitor (IB). 
Upon proper stimulation, IB is phosphorylated and dissociates from the complex, allowing 
NF-B to translocate to the nucleus where it acts as a transcription factor. The most 
attractive feature of melanocortins is that they reduce production of a variety of 
inflammatory mediators but do not enterily suppress the inflammatory response. -MSH is 
able to inhibit the activation of NF-B induced by a great diversity of inflammatory stimuli 
in different cell lines (Manna & Aggarwal, 1998), and in brain inflammation (Ichiyama et al., 
1999). This inhibitory action, thought to be the main mechanism responsible for the anti-
inflammatory effects of melanocortins, appears to be mediated by cAMP production and 
PKA activation (Manna & Aggarwal, 1998). -MSH regulates NF-κB and also p38-MAPK 
pathways probably through a common upstream element by inducing the binding of the IL-
1R-associated kinase 1 (IRAK 1) to its inhibitor IRAK-M in activated macrophages (Taylor, 
2005). However, NF-B inhibition might not be the mechanism of action of melanocortins in 
all cell types studied. Apart from NF-B, melanocortins activate CREB, a transcription factor 
acting on cell proliferation, differentiation and survival. It also regulates the expression of 
genes involved in immune responses and long term memory. In rat astrocytes, MC4R 
activation by -MSH stimulates the cAMP-PKA-CREB pathway without involving 
inhibition of NF-B (Caruso et al., 2011). CREB activation by -MSH occurs in hypothalamic 
neurons as well, and also without modifying NF-B activation (Caruso et al., 2010). 
Similarly, -MSH failure to modify NF-B activation was reported in H4 glioma cells 
(Sarkar et al., 2003).  
Another important mediator in -MSH effects is IL-10, an anti-inflammatory cytokine 
capable of inhibiting NF-B activity and the release of many pro-inflammatory mediators 
such as IL-1, IL-6, TNF-, and IL-8 (Sabat et al., 2010). This cytokine is induced by -MSH in 
monocytes and keratinocytes, and knock-out mice for IL-10 were found to be resistant to -
MSH treatment in a model of allergic inflammation (Raap et al., 2003), strongly supporting a 
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role for IL-10 as a mediator in melanocortin effect. Furthermore, a MC3R/4R antagonist, 
SHU9119, reduces LPS-induced IL-10 release in monkeys (Vulliémoz et al., 2006), thereby 
establishing a physiological role for endogenous melanocortins as modulators of this 
cytokine’s release. 
4. Neuroprotective effects of melanocortins 
Melanocortins neuroregenerative actions were described long ago. The first reports showed 
that melanocortin peptides improve nerve regeneration following peripheral nerve injury. 
ACTH administration improved recovery of adrenalectomized rats subjected to sciatic nerve 
denervation (Strand & Kung, 1980). -MSH and ACTH also induced recovery after crushing 
the sciatic nerve (Bijlsma et al., 1983). -MSH-like peptides stimulate neurite outgrowth in 
peripheral nerve injury in vivo (Plantinga et al., 1995), and axonal outgrowth from fetal 
spinal cord slices (van der Neut et al., 1988), and regrowth of injured axons in rat adult 
spinal cord (Joosten et al., 1999). Endogenous -MSH also improved recovery of rats with 
destruction of dopamine neurons of the nucleus accumbens (Wolterink et al., 1990). Its 
analog MTII also induced nerve regeneration and neuroprotection by preventing toxic 
neuropathy induced by cisplatin (Ter Laak et al., 2003). Several studies suggested that 
MC4R is the receptor involved in the neuroregenerative properties of melancortins. -MSH-
induced neurite-like outgrowth in the neuroblastoma cell line 2A was shown to be blocked 
with a specific MC4R antagonist (Adan et al., 1996). The MC4R agonist ME10501 is 
neuroprotective in spinal cord injury (Sharma et al., 2006). In mouse dorsal root ganglia 
neuron cultures, -MSH promoted neurite outgrowth, an effect entirely inhibited by a 
selective MC4R blocker, JKC-363 (Tanabe et al., 2007). This study also showed that only 
MC4R mRNA expression was induced after sciatic nerve injury, suggesting that MC4R 
could play a central role in nerve regeneration. The mechanism of neurotrophic effects of 
melanocortins remains largely unknown although it is suggested to be a consequence of the 
anti-inflammatory effects of these peptides.  
Several models of brain injury were shown to improve after melanocortin treatment. In rats 
subjected to four-vessel occlusion global cerebral ischemia, i.p. administration of -MSH 
prevented CA1 pyramidal cell death and reduced glial activation (Forslin Aronsson et al., 
2006). NDP-MSH protects hippocampal neurons from dying after cerebral ischemia in 
gerbils (Giuliani et al., 2006), and after excitotoxicity (Forslin Aronsson et al., 2007). Also, 
delayed treatment with -MSH diminished stratial damage and neuronal death after focal 
cerebral ischemia (Giuliani et al., 2007a). Melanocortins reduced hippocampal damage and 
improve learning and memory as long as 50 days after ischemia (Giuliani et al., 2009). These 
studies showed that neuroprotection by melancortins involved MC4R whereas the selective 
MC3R agonist -MSH had no protective effect on cerebral ischemia (Giuliani et al., 2006). In 
addition, melanocortins through MC4R blocked memory impairment (Gonzalez et al., 2009) 
as well as memory reconsolidation impairment (Machado et al., 2010) induced by IL-1 
administration in the hippocampus. We showed that MC4R activation protects astrocytes 
from apoptosis induced by LPS+IFN- (Caruso et al., 2007), and other authors showed that it 
also protects hypothalamic neurons from serum deprived-induced apoptosis (Chai et al., 
2006). Protection of astrocytes by melanocortins involved decreasing caspase 3 activity 
induced by LPS+IFN- and inducing expression of the anti-apoptotic protein Bcl-2 as well as 
decreasing expression of the apoptotic protein Bax induced by LPS+IFN- (Caruso et al., 
www.intechopen.com
 
Neurodegeneration 
 
104 
2007). This protective effect was also shown to involve ERK activation in a cell line of 
hypothalamic neurons (Chai et al., 2006). These data strongly suggest that melanocortins are 
neuroprotective through MC4R. 
A common feature of neurodegenerative diseases is chronic immune activation in the brain. 
Cytokines have a dual role in inflammation and disease. They contribute to the acute phase 
of inflammation but also play protective roles in later stages of injury. This is also the case in 
neurodegeneration: given that IL-1 and TNF- are increased in neurodegenerative diseases 
such as AD, PD, and MS, they are believed to be involved in the etiology of these 
pathologies. However, the role of inflammation in the development of neurodegenerative 
disorders is not clear. A general understanding indicates that inflammatory processes 
contribute to the onset of neurodegenerative diseases. Although there is no evidence of 
melanocortin effects on models of PD or AD, anti-inflammatory therapies such as 
nonsteroidal anti-inflammatory drugs (NSAIDs) were neuroprotective (Asanuma & 
Miyazaki, 2008; McGeer & McGeer, 2007). However, the use of NSAIDs for long periods of 
time can have undesired side effects. Melanocortins could be a better approach for treating 
these disorders since they could preserve the benefits of the inflammatory response and at 
the same time prevent its harmful effects. In fact, -MSH was suggested to be useful in the 
treatment of inflammatory experimental autoimmune encephalomyelitis (EAE), a T-cell 
mediated inflammatory autoimmune process that resembles the human demyelinating 
disease MS. Alterations in plasma concentrations of -MSH were shown to occur during 
exacerbation of MS (Sandyk & Awerbuch, 1992). However, in cerebrospinal fluid of MS 
patients concentrations of -MSH-like peptides were normal (Pinessi et al., 1992). Orally 
administered -MSH can reduce signs of EAE and inhibit CNS inflammation by reducing 
Th1-cytokines released by CNS lymphocytes (Brod & Hood, 2011). Injection of -MSH at the 
onset of EAE also profoundly diminished the severity of EAE in mice (Taylor & Kitaichi, 
2008). Furthermore, it was shown that modified T- cells that express and release -MSH 
reduce the signs of this disease when they are transferred into mice with EAE, suggesting 
the possibility of their use in future therapeutic applications (Han et al., 2007). 
Astrocytes actions help neurons to perform their physiological functions and contribute to 
maintain brain homeostasis. They have both beneficial and damaging responses in the CNS. 
Astrocytes proliferate in response to trauma and provide an environment that can help 
neurons to survive injury. They are activated by pro-inflammatory agents or by injury and 
contribute to brain-repair processes, but when inflammation is chronic their sustained 
activation can have harmful effects. Astrogliosis was found to be present in 
neurodegenerative diseases (Maragakis & Rothstein, 2006). However, mice deficient in glial 
fibrillary acidic protein having consequently impaired astrocyte functions develop more 
severe EAE disease compared to wild type mice (Liedtke et al., 1998). Astrocytes are able to 
produce neurotrophic factors that can promote neuron survival. We recently showed that 
MC4R activation induces expression of BDNF in rat astrocytes (Caruso et al., 2011). BDNF 
has proved to be neuroprotective in AD, MS and PD (Nagahara & Tuszynski, 2011). Indeed, 
MS patients have decreased levels of BDNF compared to healthy controls (Frota et al., 2009). 
Therefore, BDNF is a possible mediator of melanocortin action in the brain. It is likely that 
melanocortins may induce neuroprotective genes such as Bcl-2 and BDNF, thereby 
contributing to ameliorate neurodegenerative diseases. However, much study is needed to 
prove this hypothesis. 
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5. Conclusions 
Acute inflammatory response usually ends once the insult is eliminated and tissue is 
repaired. If this does not occur, inflammation becomes chronic, leading to harmful effects. 
Since local inflammation is necessary for pathogen clearance, tissue recovery and 
regeneration, ideal anti-inflammatory agents should prevent exacerbated immune reaction 
without completely eliminating inflammatory response. Thus, modulation rather than 
abolishment of inflammation seems to be the best option, and provides an opening to new 
treatment approaches in acute and chronic diseases of the CNS. Melanocortins are suitable 
candidates for this task. Their anti-inflammatory properties are well known and they also 
have neuroregenerative and neuroprotective properties that can help preserve neuron 
function. However, in view of the variety of effects produced by these peptides, we need to 
develop more selective and potent agonists for each receptor in order to avoid undesired 
side effects. Neurodegenerative diseases are tightly linked to chronic inflammation. The 
extent to which inflammatory mediators functionally impair cognition and memory is 
largely unknown. Astrocytes in particular might be especially attractive and 
underappreciated targets for neurodegenerative disease therapeutics. Finally, future studies 
need to determine the underlying mechanisms of inflammation that lead to 
neurodegeneration in order to advance towards the development of effective treatments for 
neurodegenerative diseases. 
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